{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:51:02Z","timestamp":1782280262003,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Health Research Board of Ireland","award":["EIA 2017 054"],"award-info":[{"award-number":["EIA 2017 054"]}]},{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We surveyed evidence published by Ireland\u2019s National Centre for Pharmacoeconomics (NCPE) on the cost-effectiveness of cancer drugs approved for funding within the Irish public healthcare system. The purpose is threefold: to assess the completeness and clarity of publicly available cost-effectiveness data of such therapies; to provide summary estimates of that data; to consider the implications of constraints on data availability for accountability regarding healthcare resource allocation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The National Cancer Control Programme lists 91 drug-indication pairs approved between June 2012 and July 2020. Records were retrieved from the NCPE website for each drug-indication pair, including, where available, health technology assessment (HTA) summary reports. We assessed what cost-effectiveness data regarding approved interventions is available, aggregated it and considered the consequences of reporting constraints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 91 drug-indication pairs 61 were reimbursed following full HTA, 22 after a rapid review process and 8 have no corresponding NCPE record. Of the 61 where an HTA report was available, 41 presented costs and quality-adjusted life-year (QALY) estimates of the interventions compared. Cost estimates and corresponding incremental cost-effectiveness ratios (ICERs) are based on prices on application for reimbursement. Reimbursed prices are not published. Aggregating over the drug-indication pairs for which data is available, we find a mean incremental health gain of 0.85 QALY and an aggregate ICER of \u20ac100,295\/QALY, which exceeds Ireland\u2019s cost-effectiveness threshold of \u20ac45,000\/QALY.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Reimbursement applications by pharmaceutical manufacturers for cancer drugs typically exceed Ireland\u2019s cost-effectiveness threshold, often by a considerable margin. On aggregate, the additional total net cost of new drugs relative to current treatments needs to be more than halved for the prices sought on application to be justified for reimbursement. Commercial confidentiality regarding prices and cost-effectiveness upon reimbursement compromises accountability regarding the fair and efficient allocation of scarce healthcare resources.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-021-01365-2","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T08:16:48Z","timestamp":1630311408000},"page":"375-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability"],"prefix":"10.1007","volume":"23","author":[{"given":"Suaad","family":"Almajed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Dhuhaibawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-7647","authenticated-orcid":false,"given":"Niall","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gaule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-7388","authenticated-orcid":false,"given":"James F.","family":"O\u2019Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"issue":"10","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","volume":"12","author":"R Sullivan","year":"2011","unstructured":"Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N.J., Amir, E., et al.: Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933\u2013980 (2011)","journal-title":"Lancet Oncol."},{"issue":"6","key":"1365_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1586\/14737167.7.6.605","volume":"7","author":"M Barry","year":"2007","unstructured":"Barry, M., Tilson, L.: Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev. Pharmacoecon. Outcomes Res. 7(6), 605\u2013611 (2007)","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"1365_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40274-019-6268-9","volume":"838","author":"E Connolly","year":"2019","unstructured":"Connolly, E.: Pharmacoeconomic evaluation in Ireland: review of process, timeline. PharmacoEcono. Outcomes News. 838, 23\u201325 (2019)","journal-title":"PharmacoEcono. Outcomes News."},{"issue":"12","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s40273-016-0437-5","volume":"34","author":"L McCullagh","year":"2016","unstructured":"McCullagh, L., Barry, M.: The pharmacoeconomic evaluation process in Ireland. Pharmacoeconomics 34(12), 1267\u20131276 (2016)","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2018.10.011","volume":"22","author":"A Murphy","year":"2019","unstructured":"Murphy, A., Redmond, S.: To HTA or not to HTA: identifying the factors influencing the rapid review outcome in Ireland. Value Health. 22(4), 385\u2013390 (2019)","journal-title":"Value Health."},{"issue":"4","key":"1365_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/11318790-000000000-00000","volume":"28","author":"L Tilson","year":"2010","unstructured":"Tilson, L., O\u2019Leary, A., Usher, C., Barry, M.: Pharmacoeconomic evaluation in Ireland. Pharmacoeconomics 28(4), 307\u2013322 (2010)","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1365_CR7","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s41669-019-0136-1","volume":"3","author":"C Usher","year":"2019","unstructured":"Usher, C., McCullagh, L., Tilson, L., Barry, M.: Analysis of health technology assessments of orphan drugs in Ireland from 2012 to 2017. PharmacoEconomics-open. 3(4), 583\u2013589 (2019)","journal-title":"PharmacoEconomics-open."},{"issue":"1","key":"1365_CR8","first-page":"34","volume":"4","author":"A Murphy","year":"2017","unstructured":"Murphy, A., Redmond, S.: Rapid reviews with health-technology assessments in reimbursement systems\u2014an examination of Ireland as a case study. Glob. Reg. Health Technol. Assess. 4(1), 34\u201340 (2017)","journal-title":"Glob. Reg. Health Technol. Assess."},{"key":"1365_CR9","unstructured":"Oireachtas \u00c9ireann. Health (pricing and supply of medical goods) Act 2013. http:\/\/www.irishstatutebook.ie\/pdf\/2013\/en.act.2013.0014.pdf. Accessed 31 Aug 2020."},{"key":"1365_CR10","unstructured":"IPHA. D, DoH., & HSE,. Framework Agreement on the Supply and Pricing of Medicines 2016. https:\/\/www.ipha.ie\/getattachment\/About-Us\/Our-Role\/Agreement-on-the-Supply-of-Medicines\/FINAL-FRAMEWORK-AGREEMENT-ON-THE-SUPPLY-AND-PRICING-OF-MEDICINES.pdf. Accessed 31 Aug 2020."},{"issue":"11","key":"1365_CR11","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40273-017-0552-y","volume":"35","author":"L McCullagh","year":"2017","unstructured":"McCullagh, L., Schmitz, S., Barry, M., Walsh, C.: Examining the feasibility and utility of estimating partial expected value of perfect information (via a nonparametric approach) as part of the reimbursement decision-making process in Ireland: application to drugs for cancer. Pharmacoeconomics 35(11), 1177\u20131185 (2017)","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1365_CR12","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jval.2020.09.003","volume":"23","author":"J Leahy","year":"2020","unstructured":"Leahy, J., Hickey, C., McConnell, D., Cassidy, O., Trela-Larsen, L., Barry, M., et al.: Coronavirus disease 2019: Considerations for health technology assessment from the National Centre for Pharmacoeconomics Review Group. Value Health. 23(11), 1423\u20131426 (2020)","journal-title":"Value Health."},{"key":"1365_CR13","unstructured":"HIQA. Guidelines for the Economic Evaluation of Health Technologies in Ireland 2020. https:\/\/www.hiqa.ie\/sites\/default\/files\/2020-09\/HTA-Economic-Guidelines-2020.pdf. Accessed 28 Oct 2020."},{"key":"1365_CR14","unstructured":"NCPE. Submission Process. http:\/\/www.ncpe.ie\/submission-process\/. Accessed 28 Oct 2020."},{"key":"1365_CR15","unstructured":"NCPE. Rapid Review Template: National Centre for Pharmacoeconomics. http:\/\/www.ncpe.ie\/submission-process\/submission-templates\/rapid-review-template\/. Accessed 7 Jan 2021."},{"key":"1365_CR16","unstructured":"Irish Independent. New cancer drug hailed as 'game changer' by experts 2015. https:\/\/www.independent.ie\/irish-news\/health\/new-cancer-drug-hailed-as-game-changer-by-experts-31271305.html. Accessed 7 Jan. 2021."},{"key":"1365_CR17","unstructured":"Irish Independent. Brave Vicky starts on new cancer wonder drug 2018. https:\/\/www.independent.ie\/irish-news\/courts\/brave-vicky-starts-on-new-cancer-wonder-drug-36830609.html. Accessed 7 Jan 2021."},{"key":"1365_CR18","unstructured":"NCPE. NCPE Recommendations. http:\/\/www.ncpe.ie\/submission-process\/public-consultation-2\/. Accessed: 28 Oct 2020."},{"key":"1365_CR19","unstructured":"HSE. Information about National Cancer Control Programme. https:\/\/www.hse.ie\/eng\/about\/foi-publication-scheme\/services\/cancer-control\/. Accessed 31 Aug 2020."},{"key":"1365_CR20","unstructured":"HSE. NCCP Technology Review Committee. https:\/\/www.hse.ie\/eng\/services\/list\/5\/cancer\/profinfo\/medonc\/trc\/nccp%20trc%202020.pdf. Accessed 28 Oct 2020."},{"key":"1365_CR21","unstructured":"HSE. Cancer Drugs Approved for Reimbursement. https:\/\/www.hse.ie\/eng\/services\/list\/5\/cancer\/profinfo\/medonc\/cdmp\/new.html. Accessed 31 Aug 2020."},{"key":"1365_CR22","unstructured":"HSE. Drugs Group Minutes. https:\/\/www.hse.ie\/eng\/about\/who\/cpu\/drugs-group-minutes\/. Accessed 31 Aug 2020."},{"key":"1365_CR23","unstructured":"HSE. Technology Review Committee. https:\/\/www.hse.ie\/eng\/services\/list\/5\/cancer\/profinfo\/medonc\/trc. Accessed 31 Aug 2020."},{"issue":"9","key":"1365_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40273-016-0406-z","volume":"34","author":"S Schmitz","year":"2016","unstructured":"Schmitz, S., McCullagh, L., Adams, R., Barry, M., Walsh, C.: Identifying and revealing the importance of decision-making criteria for health technology assessment: a retrospective analysis of reimbursement recommendations in Ireland. Pharmacoeconomics 34(9), 925\u2013937 (2016)","journal-title":"Pharmacoeconomics"},{"key":"1365_CR25","unstructured":"NCPE. http:\/\/www.ncpe.ie. Accessed 31 Aug 2020."},{"key":"1365_CR26","unstructured":"WHO. ATC\/DDD Index 2020 2019. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 31 Aug 2020."},{"key":"1365_CR27","unstructured":"European Commission. Community Register of orphan medicinal products: European Commission. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/reg_od_act.htm?sort=n. Accessed 31 Aug 2020."},{"key":"1365_CR28","unstructured":"Orphanet. https:\/\/www.orpha.net\/consor\/cgi-bin\/Drugs_Search_Disease.php?lng=EN. Accessed 31 Aug 2020."},{"issue":"1","key":"1365_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40273-015-0336-1","volume":"34","author":"JF O\u2019Mahony","year":"2016","unstructured":"O\u2019Mahony, J.F., Coughlan, D.: The Irish cost-effectiveness threshold: does it support rational rationing or might it lead to unintended harm to Ireland\u2019s health system? Pharmacoeconomics 34(1), 5\u201311 (2016)","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1365_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jval.2018.02.013","volume":"21","author":"TC Chen","year":"2018","unstructured":"Chen, T.C., Wanniarachige, D., Murphy, S., Lockhart, K., O\u2019Mahony, J.: Surveying the cost-effectiveness of the 20 procedures with the largest public health services waiting lists in Ireland: implications for Ireland\u2019s cost-effectiveness threshold. Value Health. 21(8), 897\u2013904 (2018)","journal-title":"Value Health."},{"issue":"2","key":"1365_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/14737167.2019.1552137","volume":"19","author":"N Mardetko","year":"2019","unstructured":"Mardetko, N., Kos, M., Vogler, S.: Review of studies reporting actual prices for medicines. Expert Rev. Pharmacoecon. Outcomes Res. 19(2), 159\u2013179 (2019)","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"1","key":"1365_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1470-2045(15)00486-6","volume":"17","author":"WH van Harten","year":"2016","unstructured":"van Harten, W.H., Wind, A., de Paoli, P., Saghatchian, M., Oberst, S.: Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 17(1), 18\u201320 (2016)","journal-title":"Lancet Oncol."},{"key":"1365_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s41669-017-0028-1","volume":"1","author":"S Vogler","year":"2017","unstructured":"Vogler, S., Paterson, K.R.: Can price transparency contribute to more affordable patient access to medicines? PharmacoEcon. Open. 1, 145\u2013147 (2017)","journal-title":"PharmacoEcon. Open."},{"issue":"2","key":"1365_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/13571516.2015.1045747","volume":"22","author":"A Towse","year":"2015","unstructured":"Towse, A., Pistollato, M., Mestre-Ferrandiz, J., Khan, Z., Kaura, S., Garrison, L.: European Union pharmaceutical markets: a case for differential pricing? Int. J. Econ. Bus. 22(2), 263\u2013275 (2015)","journal-title":"Int. J. Econ. Bus."},{"key":"1365_CR35","unstructured":"OECD\/European Observatory on Health Systems and Policies, Policies. Ireland: Country Health Profile 2017, State of Health in the EU: OECD Publishing, Paris\/European Observatory on Health Systems and Policies. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/state\/docs\/chp_ir_english.pdf (2017). Accessed 10 Nov 2020."},{"key":"1365_CR36","unstructured":"Bj\u00f6rnberg A, Phang AY. Euro Health Consumer Index 2018 Report: Health Consumer Powerhouse. https:\/\/healthpowerhouse.com\/media\/EHCI-2018\/EHCI-2018-report.pdf (2019). Accessed 7 July 2021."},{"key":"1365_CR37","unstructured":"WHA. Improving the transparency of markets for medicines, vaccines, and other health products: World Health Assembly 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329301\/A72_R8-en.pdf. Accessed 12 July 2021."},{"issue":"4","key":"1365_CR38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10198-020-01181-0","volume":"21","author":"F Lamrock","year":"2020","unstructured":"Lamrock, F., McCullagh, L., Tilson, L., Barry, M.: A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland. Eur. J. Health Econ. 21(4), 895\u2013901 (2020)","journal-title":"Eur. J. Health Econ."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-021-01365-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-021-01365-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-021-01365-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T20:34:35Z","timestamp":1648586075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-021-01365-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s10198-021-01365-2","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}